 |
|
When Does Parkinson Disease Start?
Rodolfo Savica, MD, MSc;
Walter A. Rocca, MD, MPH;
J. Eric Ahlskog, PhD, MD
Arch Neurol. 2010;67(7):798-801. doi:10.1001/archneurol.2010.135
ABSTRACT
There is convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathological findings or striatal dopamine imaging suggested a 5- to 6-year preclinical period. However, more recent evidence of Lewy body pathology in other neuronal populations preceding nigral involvement suggests that the preclinical phase may be much longer. Epidemiologic studies of nonmotor manifestations, such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder (RBD), and anemia, suggest that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.
INTRODUCTION
Parkinson disease (PD) is a neurodegenerative disorder that results in progressive extrapyramidal motor dysfunction primarily related to loss of dopaminergic nigrostriatal function. Longevity has substantially improved with dopamine replacement therapy1; however, advanced-stage PD motor symptoms respond incompletely to levodopa or related drugs and are now recognized to be caused by nondopaminergic mechanisms.2 Although the dopaminergic nigrostriatal pathway may still hold clues, research on the causes of PD has now extended beyond this system.
Clues relating to the causes of PD are crucially time dependent because causal factors may surface and disappear at any time during the patients' lives; however, some component causative factor(s) must be present before the first evidence of PD onset. Thus, dating the true onset of PD is important to properly direct research of predictive biomarkers and risk and protective factors.
NEUROPATHOLOGIC AND IMAGING DATA
Until recently, the dopaminergic nigrostriatal system has been assumed to be fundamental to PD, and the length of the preclinical phase has been estimated by backward extrapolation from the known rate of nigrostriatal loss from autopsy studies (Table). Extrapolation from series of postmortem brains with Lewy body pathology in the substantia nigra predicted a preclinical stage of approximately 5 years.3 Similarly, striatal fludeoxyglucose 18 dopamine positron emission tomography studies4-6 estimated a 6-year preclinical phase.
|
|
|
|
Table. Summary of Studies Suggesting a Long Premotor Phase of Parkinson Disease
|
|
|
However, the studies of Braak and colleagues17-20 emphasize that Lewy body pathology is much more widespread than previously acknowledged. The substantia nigra appears to be relatively spared early in the disease course, whereas other regions, including the lower brainstem, olfactory bulb, and autonomic nervous system, are already accumulating Lewy body pathology.17-20 Therefore, the previous estimates of the PD premotor phase that focused solely on substantia nigra now appear to be gross underestimates. The purpose of this article is to compile clinical and epidemiologic studies that have a bearing on the preclinical phase in PD in order to better estimate the PD timeline.
CLINICAL AND EPIDEMIOLOGIC DATA
Epidemiologic studies have suggested that certain neurologic or psychiatric manifestations may precede the traditional motor manifestations of PD by long periods. In addition, some epidemiologic studies have suggested the occurrence of early manifestations of PD outside the central or peripheral nervous systems (Table).
CONSTIPATION
Symptoms of dysautonomia develop in most patients during the course of PD, and constipation is probably the most common manifestation. Constipation relates to impaired colonic motility and is not simply attributable to medications.21 Previous authors22 have commented that constipation may sometimes precede the initial motor manifestations of PD. This finding was borne out in the Honolulu-Asia Aging Study,23 in which men without PD or dementia were prospectively followed up after completing a bowel-movement questionnaire. Incidental Lewy body pathology was present in nearly one-fourth of individuals with constipation (<1 bowel movement daily) compared with 6.5% of individuals without it. In an extension of that study, individuals with constipation who died without PD had significantly lower substantia nigra neuronal densities.23 Although these investigations focused on substantia nigra and locus caeruleus, other studies18, 24 have documented Lewy body pathology in the autonomic nervous system of individuals without PD.
Further studies in the Honolulu-Asia Aging cohort allow estimation of a timeline between constipation and later PD. Thus, men with constipation had a significantly greater risk of subsequent development of PD, and the mean interval from bowel-movement questionnaire to PD symptoms was 10 years (12 years to diagnosis).7 These findings were extended to women by a case-control study in Olmsted County, Minnesota, that showed an association between earlier-life constipation documented in medical records and subsequent risk of PD. Importantly, the association remained significant when restricted to constipation documented 20 or more years before the onset of PD motor manifestations.8 In summary, constipation may precede the motor symptoms of PD by at least 10 and perhaps more than 20 years (Table).
ANXIETY DISORDERS
Anxiety is common among patients with PD; it sometimes responds to dopamine replacement therapy.25 Several case-control or cohort studies suggested that anxiety may be 1 of the earliest manifestations of PD. First, in a population-based, case-control study,10 anxiety diagnoses documented in historical medical records were significantly associated with later PD, even when analyses were restricted to 20 or more years before PD. Second, the Health Professionals Follow-up Study9 showed that "phobic anxiety" was a significant risk factor for the development of PD within 4 years. Finally, the Mayo Clinic Cohort Study of Personality and Aging11 showed that patients with high scores on the anxiety scale or the composite neuroticism scale of the Minnesota Multiphasic Personality Inventory had a significantly increased risk of PD. The association with neuroticism remained significant when analyses were restricted to individuals who completed the Minnesota Multiphasic Personality Inventory between 20 and 39 years of age, suggesting preexisting manifestations well beyond 20 years before PD. In summary, anxiety and neuroticism may predate motor PD by more than 20 years (Table).
RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER
Rapid eye movement sleep behavior disorder (RBD) is common in PD and is recognized by clinicians to often precede PD motor symptoms.26 In fact, RBD has been associated with  -synucleinopathies in general, including not only PD but also dementia with Lewy bodies and multiple system atrophy.27 The precise neuroanatomical substrate for RBD has not been identified in humans, but animal studies28 localize it to the region of the pontine subcaeruleus nucleus; this region is at a brainstem level consistent with early Braak stages.17 Patients with isolated RBD have reduced dopamine in the striatum, as shown by imaging.29
In a prospective study,12 isolated RBD was found to evolve into PD in 38% of patients, with a mean interval of 12.7 years. Two patients with isolated RBD, without development of PD, underwent autopsy 15 to 20 years later; each was found to harbor Lewy body pathology.13-14 Finally, 3 patients with long-standing isolated RBD presented with newly diagnosed parkinsonism and abnormal dopamine brain imaging within 14, 16, and 38 years, respectively.15 In summary, RBD may precede PD by 12 years or more (Table).
ANEMIA
Parkinson disease may have systemic correlates outside the central or peripheral nervous systems. For example, peripheral mitochondrial function in platelets,30 lymphocytes,31 and muscle32 is consistently impaired in patients with PD compared with control individuals. However, there is a paucity of studies investigating this or other systemic abnormalities in the preclinical phase of PD.
In a population-based, case-control study, anemia was a significant risk factor for later PD, but only when it was documented long before PD (median, 20 years). The greatest association was with anemia starting 20 to 29 years before PD16; analyses restricted to anemia that occurred more than 30 years before the onset of PD still revealed a significant association (Table). However, this finding requires replication, and anemia may be a risk factor for PD rather than an early manifestation.16 Anemia has also been associated with a higher risk of Alzheimer disease.33-34
OTHER EARLY MANIFESTATIONS WITH SHORTER TIMELINES
Olfactory impairment and depression are 2 other nonmotor manifestations that have been repeatedly described in the preclinical phase of PD. However, the lag time from the appearance of these manifestations to the onset of motor manifestations of PD has not been studied adequately. The limited studies10-11,35-36 available indicate a relatively shorter lag time compared with the manifestations listed in the Table.
In the Honolulu-Asia Aging Study,35 olfactory dysfunction was associated with an increased risk of PD; however, the association was significant only for the first 4 years of follow-up. In addition, olfactory dysfunction predicted postmortem Lewy body pathology among individuals who died free of parkinsonism.36 Other investigators noted that olfactory dysfunction was significantly associated with subsequent development of PD within the ensuing 2 to 5 years among first-degree relatives of patients with PD.37-38
A number of studies39-41 suggest that depression may predate PD motor manifestations. However, studies assessing the interval from the documentation of depression to the onset of motor manifestations of PD suggested that the association becomes insignificant for depression occurring earlier than 2 years,42 5 years,10 or 10 years.43 In addition, the Mayo Clinic Cohort Study of Personality and Aging failed to reveal an association of high score on the depression scale of the Minnesota Multiphasic Personality Inventory with the long-term risk of PD.11
CONCLUSIONS
The Table summarizes several studies suggesting a relatively long premotor phase of PD. Constipation and anxiety disorders appear to be present in some patients more than 20 years before PD motor symptoms. Anemia may have a similar long preclinical time line; however, it was only documented in 1 population-based, case-control study.16 Rapid eye movement sleep behavior disorder precedes typical PD by more than 12 years in many patients. A conservative view would place the earliest evidence of Lewy body PD at least 20 years before the onset of typical motor manifestations. Thus, some initial causative factor or factors must already be present at that time.
It may, however, be overly simplistic to assume there is a continuous evolution from the inception to the full development of PD.44 Lewy body neurodegenerative processes may occur in a stepwise fashion, requiring additional causative factors to advance to the next level. In fact, such a noncontinuous evolution seems plausible, given the relative proportions of asymptomatic (incidental) Lewy body pathology vs PD in the general population. Incidental Lewy body disease is found in approximately 10% to 17% of people older than 60 years,36, 45-46 which is 5 to 10 times the frequency of PD. Therefore, in some individuals, the pathogenetic process may not advance to the full clinical syndrome without a second (or more) causative factor(s). Thus, the epidemiologic search for the causes of PD must encompass early and later factors (ie, multifactorial and multistage causes).
AUTHOR INFORMATION
Correspondence: Walter A. Rocca, MD, MPH, Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (rocca{at}mayo.edu).
Accepted for Publication: January 19, 2010.
Author Contributions: Drs Savica and Rocca had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Savica, Rocca, and Ahlskog. Analysis and interpretation of data: Savica and Ahlskog. Drafting of the manuscript: Savica and Ahlskog. Critical revision of the manuscript for important intellectual content: Rocca and Ahlskog. Administrative, technical, and material support: Savica. Study supervision: Rocca and Ahlskog.
Financial Disclosure: None reported.
Funding/Support: This study did not receive any specific funding. Dr Rocca is funded by the National Institutes of Health (grants AR030582, AG006786, and ES010751).
Additional Contributions: Barbara J. Balgaard, BS, typed the manuscript.
Author Affiliations: Division of Epidemiology, Department of Health Sciences Research, (Drs Savica and Rocca), and Department of Neurology (Drs Savica, Rocca, and Ahlskog), College of Medicine, Mayo Clinic, Rochester, Minnesota.
REFERENCES
1. Elbaz A, Bower JH, Peterson BJ; et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol. 2003;60(1):91-96.
FREE FULL TEXT
2. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology. 2007;69(17):1701-1711.
FREE FULL TEXT
3. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301.
FREE FULL TEXT
4. Hilker R, Schweitzer K, Coburger S; et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62(3):378-382.
FREE FULL TEXT
5. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 1996;119(pt 2):585-591.
FREE FULL TEXT
6. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64(3):314-319.
FREE FULL TEXT
7. Abbott RD, Petrovitch H, White LR; et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57(3):456-462.
FREE FULL TEXT
8. Savica R, Carlin JM, Grossardt BR; et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology. 2009;73(21):1752-1758.
FREE FULL TEXT
9. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003;18(6):646-651.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
10. Shiba M, Bower JH, Maraganore DM; et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000;15(4):669-677.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
11. Bower JH, Grossardt BR, Maraganore DM; et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord. In press.12. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46(2):388-393.
FREE FULL TEXT
13. Uchiyama M, Isse K, Tanaka K; et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology. 1995;45(4):709-712.
FREE FULL TEXT
14. Boeve BF, Dickson DW, Olson EJ; et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 2007;8(1):60-64.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
15. Stiasny-Kolster K, Doerr Y, Möller JC; et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for -synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(pt 1):126-137.
FREE FULL TEXT
16. Savica R, Grossardt BR, Carlin JM; et al. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology. 2009;73(17):1381-1387.
FREE FULL TEXT
17. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
18. Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric -synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396(1):67-72.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
19. Braak H, Sastre M, Bohl JRE, de Vos RAI, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113(4):421-429.
FULL TEXT
| PUBMED
20. Beach TG, Adler CH, Lue L; et al, Arizona Parkinson's Disease Consortium. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol. 2009;117(6):613-634.
FULL TEXT
| PUBMED
21. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology. 1992;42(4):726-732.
FREE FULL TEXT
22. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997;12(6):946-951.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
23. Petrovitch H, Abbott RD, Ross GW; et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009;24(3):371-376.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
24. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F; et al. Do -synuclein aggregates in autonomic plexuses predate Lewy body disorders? a cohort study. Neurology. 2007;68(23):2012-2018.
FREE FULL TEXT
25. Ahlskog JE. Parkinson's Disease Treatment Guide for Physicians. New York, NY: Oxford University Press; 2009.26. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123(pt 2):331-339.
FREE FULL TEXT
27. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16(4):622-630.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
28. Boeve BF, Silber MH, Saper CB; et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130(pt 11):2770-2788.
FREE FULL TEXT
29. Eisensehr I, Linke R, Tatsch K; et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters: IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep. 2003;26(5):507-512.
WEB OF SCIENCE
| PUBMED
30. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26(6):719-723.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
31. Shinde S, Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurol India. 2006;54(4):390-393.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
32. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD Jr, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci. 1991;104(2):203-208.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
33. Peters R, Burch L, Warner J, Beckett N, Poulter R, Bulpitt C. Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr. 2008;8:18.
FULL TEXT
| PUBMED
34. Atti AR, Palmer K, Volpato S, Zuliani G, Winblad B, Fratiglioni L. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging. 2006;27(2):278-284.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
35. Ross GW, Petrovitch H, Abbott RD; et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 2008;63(2):167-173.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
36. Ross GW, Abbott RD, Petrovitch H; et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062-2067.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
37. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004;56(2):173-181.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
38. Ponsen MM, Stoffers D, Twisk JWR, Wolters EC, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord. 2009;24(7):1060-1065.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
39. Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand. 2002;106(3):202-211.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
40. Schuurman AG, van den Akker M, Ensinck KTJL; et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002;58(10):1501-1504.
FREE FULL TEXT
41. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003;18(4):414-418.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
42. Alonso A, García Rodriguez LA, Logroscino G, Hernán MA. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry. 2009;80(6):671-674.
FREE FULL TEXT
43. Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson's disease in Indian patients. J Neurol Sci. 2001;190(1-2):49-55.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
44. Frigerio R, Fujishiro H, Ahn TB; et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies [published online June 26, 2009]? Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.05.019.
PUBMED
45. Klos KJ, Ahlskog JE, Josephs KA; et al. -Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology. 2006;66(7):1100-1102.
FREE FULL TEXT
46. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of -synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115(4):399-407.
FULL TEXT
| PUBMED
SECTION EDITOR: DAVID E. PLEASURE, MD
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Prospective Research on Parkinson Nonmotor Symptoms
Honglei Chen, Xiang Gao, and Alberto Ascherio
Arch Neurol. 2011;68(1):137.
EXTRACT
| FULL TEXT
Prospective Research on Parkinson Nonmotor Symptoms—Reply
Rodolfo Savica, Walter A. Rocca, and J. Eric Ahlskog
Arch Neurol. 2011;68(1):137-138.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Parkinson disease: The enteric nervous system spills its guts
Derkinderen et al.
Neurology 2011;77:1761-1767.
ABSTRACT
| FULL TEXT
Management of sexual dysfunction in Parkinson's disease
Bronner and Vodusek
Therapeutic Advances in Neurological Disorders 2011;4:375-383.
ABSTRACT
Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection
Srinivasan et al.
Therapeutic Advances in Neurological Disorders 2011;4:297-317.
ABSTRACT
Prospective Research on Parkinson Nonmotor Symptoms
Chen et al.
Arch Neurol 2011;68:137-137.
FULL TEXT
Prospective Research on Parkinson Nonmotor Symptoms--Reply
Savica et al.
Arch Neurol 2011;68:137-138.
FULL TEXT
Current understanding and management of Parkinson disease: Five new things
Morley and Hurtig
Neurology 2010;75:S9-S15.
FULL TEXT
PGC-1{alpha}, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
Zheng et al.
Sci Transl Med 2010;2:52ra73-52ra73.
ABSTRACT
| FULL TEXT
|
